Effect of Intra-articular Injection on Temporomandibular Joint Dysfunction
- Conditions
- Temporomandibular Joint Dysfunction
- Interventions
- Behavioral: Routine rehabilitation treatmentProcedure: Intra-articular Injection
- Registration Number
- NCT06213675
- Lead Sponsor
- Zeng Changhao
- Brief Summary
The goal of this clinical trial is to study about the clinical effect of Intra-articular Injection on Temporomandibular Joint Dysfunction
The main question it aims to answer is:
• Can Intra-articular Injection help improve the Temporomandibular Joint Dysfunction Participants will be randomly assigned into the experimental group and the control group, all under comprehensive treatment. The experimental group will be given Intra-articular Injection additionally, The study lasts 15 days for each patient. Researchers will compare the assessments between the two groups to see if Intra-articular Injection can help improve the Temporomandibular Joint Dysfunction
- Detailed Description
The background of Temporomandibular Joint Dysfunction is that it is one of the common diseases in the oral and maxillofacial region, and it is the most common among temporomandibular joint diseases. It is more prevalent in young adults, with the highest prevalence rate at 20-30 years old.
The goal of this clinical trial is to study about the clinical effect of Intra-articular Injection on Temporomandibular Joint Dysfunction
The main question it aims to answer is:
• Can Intra-articular Injection help improve the Temporomandibular Joint Dysfunction Participants will be randomly assigned into the experimental group and the control group, all under comprehensive treatment. The experimental group will be given Intra-articular Injection additionally, The study lasts 15 days for each patient. Researchers will compare the assessments between the two groups to see if Intra-articular Injection can help improve the Temporomandibular Joint Dysfunction
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Presence of significant temporomandibular disorder clinical symptoms.
- Meeting the diagnostic criteria for Temporomandibular Joint Dysfunction and confirmed by X-ray examination.
- Patients voluntarily participate in this study and provide signed informed consent.
- Normal cognitive function
- Rheumatic, rheumatoid, or other severe systemic diseases.
- Infectious temporomandibular joint arthritis or joint tumors.
- Individuals who have recently received joint injection treatment or photodynamic therapy.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description The control group Routine rehabilitation treatment The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients are given routine rehabilitation treatment. the experimental group Intra-articular Injection The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients in the experimental group are given routine rehabilitation treatment and intra-articular injections. Lidocaine is used as the injected medication at a dose of 2ml, administered once every 5 days for a total of three injections. the experimental group Routine rehabilitation treatment The patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients in the experimental group are given routine rehabilitation treatment and intra-articular injections. Lidocaine is used as the injected medication at a dose of 2ml, administered once every 5 days for a total of three injections.
- Primary Outcome Measures
Name Time Method Friction Index day 1 and day 15 Friction Index is used to assess temporomandibular function. The total scores range from 0 to 57, with higher scores indicating more severe temporomandibular dysfunction.
- Secondary Outcome Measures
Name Time Method The maximum mouth opening limit day 1 and day 15 The maximum mouth opening limit is measured with precision to 0.1 mm (the distance between the upper and lower lips).
Mann Assessment of Swallowing Ability day 1 and day 15 Mann Assessment of Swallowing Ability is used to assess swallowing function. The maximum score on the scale is 200. Each item on the scale is scored from 0 to 6, and the total score is calculated by summing up the scores across all items. A higher score indicates better swallowing ability, while a lower score suggests the presence of swallowing difficulties.
The Visual Analog Scale day 1 and day 15 The Visual Analog Scale is used to assess the pain levels of two groups of patients. The total score ranges from 0 to 10, with higher scores indicating more severe pain.
Trial Locations
- Locations (1)
Zheng Da yi Yuan Hospital
🇨🇳Zhengzhou, Henan, China